Articles On Opthea (ASX:OPT)

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Emerging Australian biotechnology company Opthea (ASX:OPT) has announced that the first patient has been treated in the phase three pivotal clinical program of its first-in-class VEGF-C/D ‘trap’ inhibitor.

Source: Zolnierek, Shutterstock Summary Opthea Limited announced the commencement of dosing in the pivotal Phase 3 clinical trial of OPT-302. The biopharmaceutical company would evaluate primary and secondary endpoints in the Phase 3...

Opthea (ASX:OPT) says it has finalised the protocol study designs and key start-up activities in readiness for the initiation of the phase three ShORe and COAST pivotal clinical trials of OPT-302 in wet age-related macular degenerat...

Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has welcomed seasoned drug development expert Dr Megan Baldwin to the board as an independent non-executive director, effective today. Dr Baldwin has more than two decad...

Megan Baldwin, a biotech executive well-known as CEO of Opthea (ASX:OPT), has come onboard another ASX biotech stock. Dr Baldwin ... Read More The post Megan Baldwin just joined the board of this ASX biotech stock appeared first on Stockhea...

Invex Therapeutics (ASX: IXC) is aiming to hit some significant milestones in 2021 in its bid to use a diabetic drug for a neurological condition in desperate need for treatment. The biopharmaceutical company is focused on repurposing the d...

Biopharmaceutical company Opthea is poised to undertake two phase-3 trials for its treatment to improve vision for those affected by macular degeneration -OPT-302 designed to achieve broader suppression of wAMD-Trial data anticipated in the...

During October the ASX200 outperformed most developed markets peers, with the financial and technology sectors leading the way. -The ASX200 climbed 1.9% during October-Banks rose and technology outperformed-JPMorgan sees AUD/USD at 68c by y...

More than a dozen ASX stocks, mostly in healthcare, are dual-listed in America. Another ASX stock is about to join ... Read More The post ASX stocks in America: Opthea’s about to join the ranks but who’s there already? appeared first on Sto...

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a strong gain. At the time of writing, the benchmark index is up 1% to 6,240.2 points. Four shares that have failed to follow the market higher...

Australian clinical-stage biopharmaceutical company Opthea (ASX:OPT) has launched its initial public offering of American Depositary Shares.

One side of the Australian share market which I think is a great place to look for investment ideas is the mid cap space. I’m a big fan of mid cap shares as they offer stronger potential returns than large caps, but arguably carry less ris...

Summary ASX and TSX listed Company Orocobre Limited disclosed the successful completion of its SPP by raising almost A$43 million, which is A$13 million above from its original target. ASX 300 listed PointsBet Holdings Limited disclosed...

Summary Opthea Limited disclosed that the Company had filed a registration statement for proposed Initial Public Offering (IPO) in the US. The Company also aims to list the American Depositary Shares (ADSs) on the Nasdaq Global Market u...

25 Sep 2020 - Biopharmaceutical company Opthea (ASX:OPT) has revealed plans to list American depositary receipts on the Nasdaq index.

I continue to believe that the healthcare sector is a great place to invest with a long term view. This is due to favourable industry tailwinds which look set to support demand for healthcare services for a long time to come. While I think...

Today we will look at why we like Opthea Limited (ASX OPT). Opthea Limited is an emerging healthcare company that specialises in developing novel treatments for chronic eye diseases such as age-related macular degeneration. Macular degenera...

With biotechnology in focus in 2020, Race Oncology is attracting investor interest. -2020 booming times for (some) biotechnology stocks-Race Oncology aiming to revive 1980’s Acute Myeloid Leukemia (AML) treatment-Bisantrene clinical trials...

The Opthea Ltd (ASX: OPT) share price bounced up 5% then crashed this morning after the biotech company announced plans for a listing in the United States. At the time of writing, Opthea shares had dropped back down to $2.52 after opening...

The Opthea Ltd (ASX: OPT) share price is surging higher today. This follows the release of an update on its meetings with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). At the time of writing the clini...

I think that every portfolio should have some exposure to the healthcare industry, including 1 or 2 small-caps that make up less than 5% of the total portfolio’s value. Emerging ASX biotech companies such as Opthea Ltd (ASX: OPT) and Polyn...

Long-term shareholders of emerging ASX healthcare company Opthea Ltd (ASX: OPT) have endured a volatile 12 months. A little under a year ago, the Opthea share price was trading at a 52-week low of just $0.735. Then, in the space of a month...

Like many companies, junior ASX healthcare company Medical Developments International Limited (ASX: MVP) has had a volatile 2020. After soaring to an all-time high of $11.78 in February, the Medical Developments share price was savaged in...

The Opthea Limited (ASX: OPT) share price surged more than 20% during trade today, following the company’s recent announcement about its data being presented at an upcoming industry conference.  What did Opthea announce? Earlier today, Opt...

The S&P/ASX 200 (ASX: XJO) is down over 10% compared to this time a year ago. Individual share performances have varied in the wake of the coronavirus pandemic with some surging and others wilting.  The shift to eCommerce hastened by t...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve been keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The market...

Australia’s top brokers have been busy adjusting their estimates and recommendations again, leading to the release of a large number of broker notes this week. Three broker buy ratings that have caught my eye are summarised below. Here’s w...

The journey of each individual medical treatment from idea to market requires the involvement of multiple parties big and small. The general consensus seems to be that it takes a big player to get a drug to market, which more often than not...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 134-odd small cap health stocks and of those which were trading on Wednesday, 71 were in positive territory over the last fortnight, 11 were flat and 52 saw...

As a sector, healthcare has provided some of the strongest returns over the past year. The S&P/ASX 200 Health Care Index (ASX: XHJ) has returned more than 26% over the last 12 months, comfortably outperforming the benchmark indexes for...

Having now proven its drug works on two eye diseases, Opthea (ASX:OPT) is looking to future treatment options. The immediate consideration for Opthea is a phase three study on Diabetic Macular Edema (DME), similar to its planned phase three...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Australian company Opthea (ASX:OPT) has announced topline results from a trial evaluating its biologic OPT-302 in combination with Bayer's PBS-listed EYLEA (aflibercept).

10 months since Opthea’s (ASX:OPT) drug proved itself against wet-AMD, it’s passed another clinical trial against Diabetic macular edema (DME). This morning the company conducted a 144 patient phase 2a clinical trial against DME. While it i...

Has Opthea’s (ASX:OPT) clinical trial of its drug against Diabetic macular edema (DME) been as successful as last year’s wet-AMD trial? We’re less than 24 hours from finding out. The company entered a trading halt this morning pending the r...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week As markets...

If exciting small cap ASX shares like Whispir Ltd (ASX: WSP) are too small for your tastes, then you might want to have a look at the mid cap side of the market. At this side of the market I believe there are a number of shares which have...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve been keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Healthcare is not the favourite child it was at the start of the COVID-19 pandemic, but one index measuring the sector is still up on the wider market. Biotech Daily’s top 40 index is up 14 per cent over the last month, compared to 4 per ce...

The ASX is home to a small but vibrant and growing biotechnology sector. There are a number of providers that are making significant inroads on a global scale. Here we examine 3 ASX biotech shares that have all seen strong share price rise...

The Australian drugs regulator has told sponsors of 10 products to stop marketing them for macular degeneration, a prevalent but difficult to treat eye condition affecting the elderly. Following reviews that began in 2017, the Therapeutic G...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Markets be...

Last year was a solid year for many ASX stocks and 2020 was also looking pretty good until COVID-19 struck the markets in late February. Earlier this week Reuben Adams recapped which of last year’s top mining and exploration companies have...

The Australian share market is home to a large number of mid cap shares. The good thing about this is that mid caps generally carry less risk than small caps, but stronger potential returns than large caps. This arguably makes it one of th...

Special Report: Drug developer Dimerix hasn’t been affected by the March market rout and since April has surged. What is behind this push? Shares in drug developer Dimerix (ASX:DXB) have doubled in value in the last six months and the stock...

After performing very strongly in 2019, the All Ordinaries index has given back all its gains and more in 2020. This means the index is now down a disappointing 17.2% since this time in 2019. The good news is that not all shares have given...

The S&P/ASX 200 Index (ASX: XJO) has come under significant pressure over the last couple of months due to the coronavirus pandemic. Whilst this is disappointing, one positive is that it has brought some top shares down to attractive l...